Clearstead Advisors, LLC Keros Therapeutics, Inc. Transaction History
Clearstead Advisors, LLC
- $7.4 Billion
- Q3 2025
A detailed history of Clearstead Advisors, LLC transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Clearstead Advisors, LLC holds 200 shares of KROS stock, worth $3,452. This represents 0.0% of its overall portfolio holdings.
Number of Shares
200
Previous 119
68.07%
Holding current value
$3,452
Previous $1,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding KROS
# of Institutions
169Shares Held
35.4MCall Options Held
574KPut Options Held
325K-
Adar1 Capital Management, LLC Austin, TX5.39MShares$93 Million8.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.72MShares$46.9 Million0.0% of portfolio
-
Madison Avenue Partners, LP New York, NY2.71MShares$46.7 Million3.92% of portfolio
-
Black Rock Inc. New York, NY2.51MShares$43.4 Million0.0% of portfolio
-
Western Standard LLC Los Angeles, CA2.19MShares$37.8 Million10.27% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $445M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...